Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 12/20 | 0.76 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810001 | 0.92 | HRAS (0.77) | HRASFNTAFNTBMMEECE1 | |
| SCHEMBL6812796 | 0.91 | HRAS (0.76) | HRASFNTAFNTBMMEECE1 | |
| SCHEMBL6814889 | 0.90 | HRAS (0.74) | HRASFNTAFNTBMMEECE1 | |
| SCHEMBL6813518 | 0.89 | HRAS (0.73) | HRASFNTAFNTBMMEECE1 | |
| SCHEMBL7650385 | 0.88 | HRAS (0.85) | HRASFNTAFNTBMMEECE1 | |
| SCHEMBL7649727 | 0.88 | HRAS (0.87) | HRASFNTAFNTBMMP3 | |
| SCHEMBL7654412 | 0.88 | HRAS (0.78) | HRASFNTAFNTBMMP3 | |
| SCHEMBL8499641 | 0.88 | HRAS (0.87) | HRASFNTAFNTBMMP3 | |
| SCHEMBL7871334 | 0.87 | HRAS (0.85) | HRASFNTAFNTBMMEECE1 | |
| SCHEMBL7647537 | 0.87 | HRAS (0.85) | HRASFNTAFNTBMMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1076663-B1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-18 | — | — | EP | claimed |
| US-6369034-B1 | FOR THERAPY OF CANCER, RESTENOSIS, AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-04-09 | — | — | US | claimed |
| EP-1076663-A1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-21 | — | — | EP | claimed |
| WO-1999055725-A1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | claimed |
| EP-1076663-B1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-02-18 | — | — | EP | disclosed |
| US-6369034-B1 | FOR THERAPY OF CANCER, RESTENOSIS, AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-04-09 | — | — | US | disclosed |
| EP-1076663-A1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055725-A1 | FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN DERIVATIVES OF GLYCINAMIDES AS FARNESYL TRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |